Home › Funds › BAKER BROS. ADVISORS LP › KNSA
BAKER BROS. ADVISORS LP position in KNSA
KINIKSA PHARMACEUTICALS INTL P ORD SHS CL A · Health Care
BAKER BROS. ADVISORS LP reported holding 2,834,643 shares of KNSA (KINIKSA PHARMACEUTICALS INTL P ORD SHS CL A) in its Q2 2026 13F filing — a position valued at US$181.3M, representing 0.95% of its reported portfolio and ranking #17 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed KNSA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BAKER BROS. ADVISORS LP's KNSA position evolved
BAKER BROS. ADVISORS LP first disclosed a stake in KNSA in Q3 2023 at 2,809,577 shares (US$48.8M). The position peaked in Q2 2026 at 2,834,643 shares, worth US$181.3M. Across 12 filings, BAKER BROS. ADVISORS LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 2,834,643 shares valued at US$181.3M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 2.81M | $48.80M | New |
| Q4 2023 | 2.81M | $49.28M | Hold |
| Q1 2024 | 2.81M | $55.43M | Hold |
| Q2 2024 | 2.82M | $52.62M | Hold |
| Q3 2024 | 2.82M | $70.43M | Hold |
| Q4 2024 | 2.82M | $55.75M | Hold |
| Q1 2025 | 2.82M | $62.59M | Hold |
| Q2 2025 | 2.82M | $78.16M | Hold |
| Q3 2025 | 2.82M | $109.68M | Hold |
| Q4 2025 | 2.83M | $116.58M | Hold |
| Q1 2026 | 2.83M | $136.08M | Hold |
| Q2 2026 | 2.83M | $181.28M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KNSA and 13F data
KNSA (KINIKSA PHARMACEUTICALS INTL P ORD SHS CL A) is a Health Care company. 48 other funds we track also report a position in KNSA — the largest reported positions include Rubric Capital Management LP (US$255.8M), TANG CAPITAL MANAGEMENT LLC (US$144.5M), Spruce Street Capital LP (US$58.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KNSA
- Rubric Capital Management LP 4.00M sh · $255.79M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 2.26M sh · $144.52M · Q2 2026
- Spruce Street Capital LP 918.07K sh · $58.71M · Q2 2026
- RICE HALL JAMES & ASSOCIATES, LLC 624.93K sh · $39.96M · Q2 2026
- ORBIMED ADVISORS LLC 420.60K sh · $26.90M · Q2 2026
- Penn Capital Management Company, LLC 368.11K sh · $23.57M · Q2 2026
- Soleus Capital Management, L.P. 246.35K sh · $15.75M · Q2 2026
- ESSEX INVESTMENT MANAGEMENT CO LLC 202.02K sh · $15.07M · Q3 2026
- ArrowMark Colorado Holdings LLC 215.55K sh · $13.78M · Q2 2026
- STEMPOINT CAPITAL LP 209.23K sh · $13.38M · Q2 2026
More on BAKER BROS. ADVISORS LP
FAQ
How long has BAKER BROS. ADVISORS LP held KNSA?
BAKER BROS. ADVISORS LP has disclosed KNSA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is BAKER BROS. ADVISORS LP's current position in KNSA?
As of Q2 2026, BAKER BROS. ADVISORS LP holds 2.83M shares of KNSA (KINIKSA PHARMACEUTICALS INTL P ORD SHS CL A), valued at $181.28M, representing 0.95% of its reported portfolio and ranking #17.
Has BAKER BROS. ADVISORS LP been buying or selling KNSA?
In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP held unchanged its position in KNSA. The position peaked in Q2 2026 at 2.83M shares.
Which other funds hold KNSA?
Other major institutional holders of KNSA include Rubric Capital Management LP, TANG CAPITAL MANAGEMENT LLC, Spruce Street Capital LP, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.